

S/N 09/806,989

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Lautt Examiner: Delacroix Muirhei,
Cybille

Serial No.: 09/806,989 Group Art Unit: 1614

Filed: May 29, 2001 Docket No.: 14217.1USWO

Title: METHOD FOR TREATING INSULIN RESISTANCE THROUGH
HEPATIC NITRIC OXIDE

CERTIFICATE UNDER 37 CFR 1.10:

"Express Mail" mailing label number:

Date of Deposit: _____

I hereby certify that this paper or fee is being deposited with the U.S. Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to: Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450.

By: _____

Name: _____

INFORMATION DISCLOSURE STATEMENT (37 C.F.R. § 1.97(d))

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

With regard to the above-identified application, the items of information listed on the enclosed Form 1449 are brought to the attention of the Examiner.

This statement should be considered because it is submitted after the mailing date of a final action under 37 C.F.R. § 1.113 or after the mailing date of the Notice of Allowance under 37 C.F.R. § 1.311 or after any other action that closes prosecution on the application, but before the payment of the issue fee. Enclosed is a check in the amount of \$ for the fee set forth in 37 C.F.R. § 1.17(p). This statement is submitted as certified below under 37 C.F.R. §1.97(e)(1) or (2) by the undersigned.

Certification Under 37 C.F.R. §1.97(e)(2)

In accordance with 37 C.F.R. §1.97(c) or §1.97(d), the undersigned hereby certifies that no item of information listed on the enclosed Form 1449 was cited in a communication from a

foreign patent office in a counterpart foreign application, and to the knowledge of the undersigned after making a reasonable inquiry, no item of information listed on the enclosed Form 1449 was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this statement.

In accordance with 37 C.F.R. §1.98(a)(2), a copy of each document or other information listed on the enclosed Form 1449 is provided.

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§ 102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or otherwise, to establish that the reference(s) are not "prior art." Moreover, Applicants do not represent that a reference has been thoroughly reviewed or that any relevance of any portion of a reference is intended.


Consideration of the items listed is respectfully requested. Pursuant to the provisions of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached Form 1449, marked as being considered and initialed by the Examiner, to the undersigned with the next official communication.

Please charge any additional fees or credit any overpayment to Deposit Account No. 13-2725.

Respectfully submitted,

MERCHANT & GOULD P.C.
P.O. Box 2903
Minneapolis, Minnesota 55402-0903
(612) 332-5300

Date: June 27, 2005



Ronald A. Daignault
Reg. No. 25,968
RDaignault:BRD:mls



FORM 1449*

INFORMATION DISCLOSURE STATEMENT

IN AN APPLICATION

(Use several sheets if necessary)

Docket Number:

14217.1USWO


Application Number:

09/806,989

Applicant: Lauth

Filing Date: May 29, 2001

Group Art Unit: 1614



U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		Bauer et al., "Nitric Oxide Donors: Biochemical Pharmacology and Therapeutics" in NITRIC OXIDE: BIOCHEMISTRY, MOLECULAR BIOLOGY AND THERAPEUTIC IMPLICATIONS 360-381 (Ignarro and Murad, eds., 1995).
		Feelisch, M. "The use of nitric oxide donors in pharmacological studies", <i>Naunyn-Schmiedeberg's Arch. Pharmacol.</i> (1998) 358: 113-122.
		Noack, E. and Feelisch, M., "Molecular Mechanisms of nitrovasodilator bioactivation", <i>Basic Res. Cardiol.</i> (1991) 86: 37-50.

23552

PATENT TRADEMARK OFFICE

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	